A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care

Cancer Prevention Research

Volumn 8, Issue 1, 2015, Pages 37-48

  Shadfan, Basil H ^a   Simmons, Archana R ^a,b   Simmons, Glennon W ^a,b   Ho, Andy ^a,b   Wong, Jorge ^a,b   Lu, Karen H ^c   Bast, Robert C ^c   McDevitt, John T ^a,b  

^a RICE UNIVERSITY   (United States)

^b Rice University   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGAROSE; BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 72-4 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; MATRILYSIN; CA-72-4 ANTIGEN; MMP7 PROTEIN, HUMAN; PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; WFDC2 PROTEIN, HUMAN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; IMMUNOASSAY ANALYZER; INCUBATION TIME; LAB ON A CHIP; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MICROFLUIDICS; NANOCHIP; NANOFLUIDICS; OVARY CANCER; POINT OF CARE TESTING; PRIORITY JOURNAL; PROGRAMMABLE BIO NANOCHIP; AUTOMATION; BLOOD; CALIBRATION; CHEMISTRY; DEVICES; EARLY CANCER DIAGNOSIS; NANOTECHNOLOGY; OVARIAN NEOPLASMS; POINT OF CARE SYSTEM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; AUTOMATION; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CALIBRATION; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOASSAY; MATRIX METALLOPROTEINASE 7; MICROFLUIDICS; NANOTECHNOLOGY; OVARIAN NEOPLASMS; POINT-OF-CARE SYSTEMS; PROTEINS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84920847952     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-14-0248     Document Type: Article

References (44)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of Screening on ovarian cancer mortality: The Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. J Am Med Assoc 2011;305:2295-303.
3. Bast RC Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass. Int J Gynecol Cancer 2012;22:S5-S8.
4. Badgwell D, Bast RC. Early detection of ovarian cancer. Dis Markers 2007;23:397-410.
5. Barakat R, Markman M, Randall ME. Principles and Practice of Gynecologic Oncology, 5th ed. In:Fleming G, Ronnett B, Seidman J, Zaino R, Rubin S. Epithelial Ovarian Cancer. Philadelphia: Lippincott Williams & Wilkins 2009;794-5.
6. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ 1993;306:1025-9.
7. Valentin L, Skoog L, Epstein E. Frequency and type of adnexal lesions in autopsy material from postmenopausal women: ultrasound study with histological correlation. Ultrasound Obstet Gynecol 2003;22:284-9.
8. Verheijen R, Mensdorff-Pouilly von S. CA 125: fundamental and clinical aspects. Semin Cancer Biol 1999;9:117-24.
9. Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Res Cancer 2007;147:91-100.
10. Menon U, Skates S, Lewis S. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol 2005;23: 7919-26.
11. Menon U, Gentry-Maharaj A, Hallett R, Ryan A. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009;10:327-40.
12. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer 2013;119:3454-61.
13. Gogoi R, Srinivasan S, Fishman DA. Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer. Expert Rev Mol Diagn 2006;6:627-37.
14. Tanyi JL, Scholler N. Oncology biomarkers for gynecologic malignancies. Front Biosci (Elite Ed) 2012;4:1097-110.
15. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010;102:26-38.
16. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010;28:2159-66.
17. O'Brien TJ, Beard JB, Underwood LJ, Shigemasa K. The CA 125 Gene: a newly discovered extension of the glycosylated N-Terminal domain doubles the size of this extracellular superstructure. Tumour Biol 2002;23:154-69.
18. O'Brien TJ, Beard JB, Underwood LJ, Dennis RA, Santin AD, York L. The CA 125 Gene: an extracellular superstructure dominated by repeat sequences. Tumour Biol 2001;22:348-66.
19. Drapkin R, Horsten von H, Lin Y, Mok S. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9.
20. Lu R, Sun X, Xiao R, Zhou L, Gao X, Guo L. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 2012;419:274-80.
21. Westermarck J, Kahari VM. Regulation ofmatrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781-92.
22. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
23. Kufe DW. Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer 2009;9:874-85.
24. Vignali D. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000;243:243-55.
25. Sorger PK. Microfluidics closes in on point-of-care assays. Nat Biotechnol 2008;26:1345-6.
26. Soper SA, Brown K, Ellington A, Frazier B, Garcia-Manero G, Gau V, et al. Point-of-care biosensor systems for cancer diagnostics/prognostics. Biosens Bioelectron 2006;21:1932-42.
27. Wu Y, Xue P, Hui KM, Kang Y. A paper-based microfluidic electrochemical immunodevice integrated with amplification-by-polymerization for the ultrasensitive multiplexed detection of cancer biomarkers. Biosens Bioelectron 2014;52:180-7.
28. Wang S, Ge L, Yan M, Yu J, Song X, Ge S, et al. 3D microfluidic origami electrochemiluminescence immunodevice for sensitive point-of-care testing of carcinoma antigen 125. Sensor Actuator B-Chem 2013;176:1-8.
29. Goodey A, Ali M, Neikirk D, McDevitt J. A microchip-based multianalyte assay system for the assessment of cardiac risk. Anal Chem 2002;74:3030-6.
30. Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, et al. Programmable Bio-Nano-Chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care. Cancer Prev Res 2012;5:706-16.
31. Weigum S, Floriano P, Christodoulides N, McDevitt J. Cell-based sensor for analysis of EGFR biomarker expression in oral cancer. Lab Chip 2007;7:995-1003.
32. Christodoulides N, Dharshan P, Wong J, Floriano PN, Neikirk D, McDevitt JT. A microchip-based assay for interleukin-6. Methods Mol Biol 2007;385:131-44.
33. Jokerst J, Jacobson J, Bhagwandin B, Floriano P, Christodoulides N, McDevitt J. Programmable nano-bio-chip sensors: analytical meets clinical. Anal Chem 2010;82:1571-9.
34. Rasooly A, Jacobson J. Development of biosensors for cancer clinical testing. Biosens Bioelectron 2006;21:1851-8.
35. Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ 1996;313:1355-8.
36. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol 2003;21:206s-10s.
37. Skates S, Jacobs I, Knapp R. Ovarian Cancer 5. Oxford: Isis Medical Media 1998;187-90.
38. Jokerst JV, Chou J, Camp JP, Wong J, Lennart A, Pollard AA, et al. Location of biomarkers and reagents within agarose beads of a Programmable Bio-Nano-Chip. Small 2011;7:613-24.
39. Urban N, Thorpe J, Karlan BY, McIntosh MW, Palomares MR, Daly MB, et al. Interpretation of single and serial measures of HE4 and CA125 in aysmptomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2012;21:2087-94.
40. Yurkovetsky ZR, Linkov FY, Malehorn DE, Lokshin AE. Multiple biomarker panels for early detection of ovarian cancer. Future Oncol 2006;2:733-41.
41. Leelawat K, Sakchinabut S, Narong S, Wannaprasert J. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy. BMC Gastroenterol 2009;9:30.
42. Ellington AA, Kullo IJ, Bailey KR, Klee GG. Antibody-based protein multiplex platforms: technical and operational challenges. Clin Chem 2010;56:186-93.
43. Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening. Cancer Prev Res 2011;4:1356-9.
44. Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom Familial Ovarian Cancer Screening Study highlight the need for strict adherence to screening schedule. J Clin Oncol 2013;31:49-57.